Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 120

Sort by

Sort Order Select

Journal Articles

Intensity-Adjusted Salvage Chemotherapy Plus FLT3-Inhibitor Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia with Mutated FLT3-ITD/TKD (SAPPHIRE-G)

Hawk Kim, Jae-Sook Ahn, Sung-Hyun Kim, Ho-Young Yhim, Sung-Nam Lim, Yoo Jin Lee, Jeong-Ok Lee, Eun-Ji Choi, Je-Hwan Lee

Blood (2024) 144 (Supplement 1): 2897.

https://doi.org/10.1182/blood-2024-201404

Published: 2024

Journal Articles

Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition

Alexander Röth, Guangsheng He, Andres Brodsky, Chatree Chai-Adisaksopha, Narcisa Sonia Comia, Anna Gaya, Martin Höglund, Richard J. Kelly, Ahlam Naila Kori, Je-Hwan Lee, Naoshi Obara, Antonio M Risitano, Anita Appius, Leigh Beveridge, Brittany Gentile, Zilu Zhang, Bing Han, Sasha Sreckovic

Blood (2024) 144 (Supplement 1): 2687.

https://doi.org/10.1182/blood-2024-208072

Published: 2024

Journal Articles

PHI-101, a Novel FLT3 TKI, Shows Clinical Efficacy in Relapsed/Refractory FLT3-Mutated AML

Blood (2024) 144 (Supplement 1): 1495.

https://doi.org/10.1182/blood-2024-207033

Published: 2024

Journal Articles

PHI-101 As a Potent Next-Generation FLT3 Inhibitor, Overcome Resistances in Previously Treated Patients with FLT3-ITD or TKD Acute Myeloid Leukemia: Results of a Phase Ia/Ib Clinical Trial

Sung-Soo Yoon, Dongyeop Shin, Je-Hwan Lee, Jun Ho Jang, June-Won Cheong, Ho-Jin Shin, Jeong-Ok Lee, Yoo Jin Lee, Joseph Clarey, Gi-Jun Sung, Kyung-Ah Kim, Ky-Youb Nam, Kyu-Tae Kim, June Han, JeongHyeok Yoon, Bao Nguyen, Li Li, Donald Small

Blood (2023) 142 (Supplement 1): 4283.

https://doi.org/10.1182/blood-2023-185606

Published: 2023

Journal Articles

The Optimal Busulfan Dose of Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation in Younger Patients with Acute Myeloid Leukemia

Yunsuk Choi, Eun-Ji Choi, Han-Seung Park, Jung-Hee Lee, Kyoo-Hyung Lee, Young-Shin Lee, Young-A Kang, Mijin Jeon, Ji Min Woo, Hyeran Kang, Je-Hwan Lee

Blood (2023) 142 (Supplement 1): 6991.

https://doi.org/10.1182/blood-2023-189327

Published: 2023

Journal Articles

Predicting Disease Progression from Idiopathic Cytopenia of Undetermined Significance to Myeloid Malignancies Using a Machine Learning-Based Approach

Eun-Ji Choi, Jiye Han, Tae Joon Jun, Han-Seung Park, Yunsuk Choi, Jung-Hee Lee, Kyoo Hyung Lee, Young-Hak Kim, Je-Hwan Lee

Blood (2023) 142 (Supplement 1): 7154.

https://doi.org/10.1182/blood-2023-188822

Published: 2023

Journal Articles

Role of Autologous or Allogeneic Stem Cell Transplantation in Patients with Peripheral T Cell Lymphomas (PTCLs)

Blood (2022) 140 (Supplement 1): 6592–6593.

https://doi.org/10.1182/blood-2022-171149

Published: 2022

Journal Articles

Antileukemic Activity of Ypn-005, a CDK7 Inhibitor, Inducing Apoptosis through c-MYC and FLT3 Suppression in Acute Myeloid Leukemia

Bon-Kwan Koo, Je-Hwan Lee, Eun-Ji Choi, Eun-Hye Hur, Ju Hyun Moon, Ji Yun Kim, Han-Seung Park, Yunsuk Choi, Jung-Hee Lee, Kyoo Hyung Lee, Jinhwan Kim

Blood (2022) 140 (Supplement 1): 8803–8804.

https://doi.org/10.1182/blood-2022-168726

Published: 2022

Journal Articles

A Potent Small Molecule Inhibitor of FLT3, PHI-101 Overcomes Resistance in Acute Myeloid Leukemia: Efficacy and PK/PD Profile in Phase 1 First in Human Study

Sung-Soo Yoon, Dong-Yeop Shin, Je-Hwan Lee, Jun Ho Jang, June-Won Cheong, Ho-Jin Shin, Jeong-Ok Lee, Yunsuk Choi, Joseph Clarey, Jeejin Im, Suntae Kim, Ky-Youb Nam, Kyu-Tae Kim, June Han, Jeong Hyeok Yoon, Bao Nguyen, Li Li, Donald Small

Blood (2022) 140 (Supplement 1): 3365–3366.

https://doi.org/10.1182/blood-2022-165000

Published: 2022

Journal Articles

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy

Blood (2022) 140 (17): 1845–1857.

https://doi.org/10.1182/blood.2021014586

Published: 2022

Includes: Supplemental data

Journal Articles

Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Cell Transplantation for Higher-Risk Myelodysplastic Syndrome

Eun-Ji Choi, Han-Seung Park, Jung-Hee Lee, Kyoo Hyung Lee, Youngshin Lee, Young-Ah Kang, Mijin Jeon, Ji Min Woo, Hyeran Kang, Je-Hwan Lee

Blood (2021) 138 (Supplement 1): 2873.

https://doi.org/10.1182/blood-2021-150389

Published: 2021

Journal Articles

Multicenter Phase II Study to Evaluate Therapeutic Efficacy of Imatinib Mesylate in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease

Dong Won Baek, Sr., Joon Ho Moon, Jae-Sook Ahn, Seong Kyu Park, Ik Chan Song, Ho-Sup Lee, Won Sik Lee, Jong Ho Won, Hong Ghi Lee, June-Won Cheong, Yeung-Chul Mun, Chul W. Jung, Je-Hwan Lee, Hyeoung-Joon Kim, Sang Kyun Sohn

Blood (2021) 138 (Supplement 1): 2889.

https://doi.org/10.1182/blood-2021-154470

Published: 2021

Journal Articles

A Phase 1a/1b First in Human Study of PHI-101, a Potent Small Molecule Inhibitor of FLT3 in Relapsed and Refractory Acute Myeloid Leukemia

Sung-Soo Yoon, Dong-Yeop Shin, Je-Hwan Lee, Jun Ho Jang, June-Won Cheong, Ho-Jin Shin, Jeong-Ok Lee, Yunsuk Choi, Anish Puliyayil, Joseph Clarey, Jeejin Im, Ky-Youb Nam, Kyu-Tae Kim, June H-J. Han, Jeong-Hyeok Yoon, Bao Nguyen, Li Li, Donald Small

Blood (2021) 138 (Supplement 1): 3425.

https://doi.org/10.1182/blood-2021-149395

Published: 2021

Journal Articles

Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy

Blood (2021) 138 (Supplement 1): 700.

https://doi.org/10.1182/blood-2021-145379

Published: 2021

Journal Articles

Similar Survival and Genetic Features between Clonal Cytopenia of Undetermined Significance and Lower-Risk Myelodysplastic Syndrome

Eun-Ji Choi, Young-Uk Cho, Han-Seung Park, Jung-Hee Lee, Kyoo Hyung Lee, Sang-Hyun Hwang, Seongsoo Jang, Chan-jeoung Park, Je-Hwan Lee

Blood (2021) 138 (Supplement 1): 3683.

https://doi.org/10.1182/blood-2021-150368

Published: 2021

Journal Articles

Machine Learning-Based Approach to Predict Survival after Allogeneic Hematopoietic Cell Transplantation in Hematologic Malignancies

Eun-Ji Choi, MDPhD, Je-Hwan Lee, MDPhD, Jun-Hong Park, MD, Han-Seung Park, MD, Jung-Hee Lee, MD PhD, Youngshin Lee, Young-Ah Kang, Mijin Jeon, Ji Min Woo, Hyeran Kang, Kyoo Hyung Lee, MD PhD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-142337

Published: 2020

Journal Articles

Clinical Implications of Copy Number Variant Detection from Panel-Based Next-Generation Sequencing Data in Myelodysplastic Syndrome

Je-Hwan Lee, MD PhD, Yoo-Jin Kim, MD PhD, Seung-Hyun Jung, Eun-Hye Hur, Eun-Ji Choi, MD, Kyoo Hyung Lee, MD PhD, Seon-Hee Yim, Hye-Jung Kim, Yong-Rim Kwon, Young-Woo Jeon, MD PhD, Sug Hyung Lee, Yeun-Jun Chung

Blood (2019) 134 (Supplement_1): 4264.

https://doi.org/10.1182/blood-2019-131570

Published: 2019

Journal Articles

DDX41 mutation in Patients with Idiopathic Cytopenia of Undetermined Significance, Myelodysplastic Syndrome, and Acute Myeloid Leukemia

Eun-Ji Choi, MD, Young-Uk Cho, MD, Seongsoo Jang, Chan-jeoung Park, Han-Seung Park, MD, Jung-Hee Lee, MD PhD, Kyoo Hyung Lee, MD PhD, Eun-Hye Hur, PhD, Nayoung Kim, PhD, Hee Jeong Ouk, MD, Je-Hwan Lee, MD PhD

Blood (2019) 134 (Supplement_1): 3002.

https://doi.org/10.1182/blood-2019-129906

Published: 2019

Journal Articles

Mutational Characteristics and Changing Pattern from Idiopathic Cytopenia of Undetermined Significance to High-Risk Myelodysplastic Syndrome Stratified By IPSS-R

Eun-Ji Choi, MD, Young-Uk Cho, MD, Seongsoo Jang, Chan-jeoung Park, Han-Seung Park, MD, Jung-Hee Lee, MD PhD, Kyoo-Hyung Lee, MD PhD, Eun-Hye Hur, PhD, Nayoung Kim, PhD, Hee Jeong Ouk, MD, Je-Hwan Lee, MD PhD

Blood (2019) 134 (Supplement_1): 3009.

https://doi.org/10.1182/blood-2019-125236

Published: 2019

Journal Articles

Decitabine Versus Intensive Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

Eun-Ji Choi, MD, Je-Hwan Lee, MD PhD, Han-Seung Park, MD, Jung-Hee Lee, MD PhD, Miee Seol, Young-Shin Lee, Young-Ah Kang, Mijin Jeon, Ji Min Woo, Kyoo Hyung Lee, MD PhD

Blood (2018) 132 (Supplement 1): 2713.

https://doi.org/10.1182/blood-2018-99-116102

Published: 2018

NARROW

Intensity-Adjusted Salvage Chemotherapy Plus FLT3-Inhibitor Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia with Mutated FLT3-ITD/TKD (SAPPHIRE-G)

Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition

PHI-101, a Novel FLT3 TKI, Shows Clinical Efficacy in Relapsed/Refractory FLT3-Mutated AML

PHI-101 As a Potent Next-Generation FLT3 Inhibitor, Overcome Resistances in Previously Treated Patients with FLT3-ITD or TKD Acute Myeloid Leukemia: Results of a Phase Ia/Ib Clinical Trial

The Optimal Busulfan Dose of Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation in Younger Patients with Acute Myeloid Leukemia

Predicting Disease Progression from Idiopathic Cytopenia of Undetermined Significance to Myeloid Malignancies Using a Machine Learning-Based Approach

Role of Autologous or Allogeneic Stem Cell Transplantation in Patients with Peripheral T Cell Lymphomas (PTCLs)

Antileukemic Activity of Ypn-005, a CDK7 Inhibitor, Inducing Apoptosis through c-MYC and FLT3 Suppression in Acute Myeloid Leukemia

A Potent Small Molecule Inhibitor of FLT3, PHI-101 Overcomes Resistance in Acute Myeloid Leukemia: Efficacy and PK/PD Profile in Phase 1 First in Human Study

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy

Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Cell Transplantation for Higher-Risk Myelodysplastic Syndrome

Multicenter Phase II Study to Evaluate Therapeutic Efficacy of Imatinib Mesylate in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease

A Phase 1a/1b First in Human Study of PHI-101, a Potent Small Molecule Inhibitor of FLT3 in Relapsed and Refractory Acute Myeloid Leukemia

Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy

Similar Survival and Genetic Features between Clonal Cytopenia of Undetermined Significance and Lower-Risk Myelodysplastic Syndrome

Machine Learning-Based Approach to Predict Survival after Allogeneic Hematopoietic Cell Transplantation in Hematologic Malignancies

Clinical Implications of Copy Number Variant Detection from Panel-Based Next-Generation Sequencing Data in Myelodysplastic Syndrome

DDX41 mutation in Patients with Idiopathic Cytopenia of Undetermined Significance, Myelodysplastic Syndrome, and Acute Myeloid Leukemia

Mutational Characteristics and Changing Pattern from Idiopathic Cytopenia of Undetermined Significance to High-Risk Myelodysplastic Syndrome Stratified By IPSS-R

Decitabine Versus Intensive Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only